Individual Differences in Glucosamine Sulfate Exposure Levels
Maneno muhimu
Kikemikali
Tarehe
| Imethibitishwa Mwisho: | 06/30/2017 |
| Iliyowasilishwa Kwanza: | 06/22/2017 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 06/26/2017 |
| Iliyotumwa Kwanza: | 06/27/2017 |
| Sasisho la Mwisho Liliwasilishwa: | 07/02/2017 |
| Sasisho la Mwisho Lilichapishwa: | 07/04/2017 |
| Tarehe halisi ya kuanza kwa masomo: | 07/01/2017 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 06/30/2019 |
| Tarehe ya Kukamilisha Utafiti: | 09/30/2019 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: Drug group
Awamu
Vikundi vya Arm
| Mkono | Uingiliaji / matibabu |
|---|---|
| Drug group patients taking glucosamine | Drug: Drug group Patients taking glucosamine sulfate 1500mg every day for at least four days. |
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 60 Years Kwa 60 Years |
| Jinsia Inastahiki Kujifunza | All |
| Njia ya sampuli | Non-Probability Sample |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | Inclusion Criteria: 1. patients undergoing total knee arthroplasty for knee osteoarthritis; 2. 60-80 years. Exclusion Criteria: 1. patients with severe liver or renal insufficiency; 2. patients allergic to glucosamine or any excipients in tablets; 3. patients who have been treated with glucosamine within three months; 4. patients who are unable to cooperate with the study; 5. continuous medication is less than 4 days; 6. patients with diarrhea, vomiting and other adverse reactions during medication. |
Matokeo
Hatua za Matokeo ya Msingi
1. Drug concentration in plasma [Fasting venous blood before the first administration]
2. Drug concentration in plasma [3 hours after the third administration]
3. Drug concentration in plasma [9 hours after the third administration]
4. Drug concentration in plasma [Fasting venous blood before the fourth administration]
5. Drug concentration in plasma [Venous blood during the operation of total knee arthroplasty]
6. Drug concentration in synovial fluid [During the operation of total knee arthroplasty]
7. Inflammatory markers in plasma [Fasting venous blood before the first administration]
8. Inflammatory markers in plasma [3 hours after the third administration]
9. Inflammatory markers in plasma [9 hours after the third administration]
10. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
11. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
12. Inflammatory markers in plasma [Fasting venous blood before the first administration]
13. Inflammatory markers in plasma [3 hours after the third administration]
14. Inflammatory markers in plasma [9 hours after the third administration]
15. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
16. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
17. Inflammatory markers in plasma [Fasting venous blood before the first administration]
18. Inflammatory markers in plasma [3 hours after the third administration]
19. Inflammatory markers in plasma [9 hours after the third administration]
20. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
21. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
22. Inflammatory markers in plasma [Fasting venous blood before the first administration]
23. Inflammatory markers in plasma [3 hours after the third administration]
24. Inflammatory markers in plasma [9 hours after the third administration]
25. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
26. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
27. Inflammatory markers in plasma [Fasting venous blood before the first administration]
28. Inflammatory markers in plasma [3 hours after the third administration]
29. Inflammatory markers in plasma [9 hours after the third administration]
30. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
31. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
32. Inflammatory markers in plasma [Fasting venous blood before the first administration]
33. Inflammatory markers in plasma [3 hours after the third administration]
34. Inflammatory markers in plasma [9 hours after the third administration]
35. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
36. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
37. Inflammatory markers in plasma [Fasting venous blood before the first administration]
38. Inflammatory markers in plasma [3 hours after the third administration]
39. Inflammatory markers in plasma [9 hours after the third administration]
40. Inflammatory markers in plasma [Fasting venous blood before the fourth administration]
41. Inflammatory markers in plasma [During the operation of total knee arthroplasty]
42. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
43. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
44. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
45. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
46. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
47. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
48. Inflammatory markers in synovial fluid [During the operation of total knee arthroplasty]
49. Gene polymorphism [Fasting venous blood before the first administration]
